Closing Remarks on Bispecific Antibodies
Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
How Administration of Bispecific T-Cell Engagers Has Evolved
A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.
The Grading and Management of Early and Late Adverse Events
Justin LaPorte, PharmD, BCOP, presents information on the grading and management of early and late adverse events.
Treating Patients With Bispecific Engagers
Discussion of the roles and responsibilities of the health care provider (physician, APP), pharmacy staff, nursing staff, and financial counselors/clinic financial manager in bispecific engager administration.
Program Development and SOPs for Bispecific Engagers
Justin LaPorte, PharmD, BCOP, further explores his experience in developing and/or executing program development and SOPs for bispecific engagers.
Overview of Bispecific Engagers Administration Program
A description and overview of the bispecific engager administration program at Northside Hospital.
Introduction to Bispecific Antibodies: Operationalizing Administration and Follow-Up
Justin LaPorte, PharmD, BCOP, introduces the purpose and objectives for the program.
